Thomas Beck leads the New York intellectual property litigation group, and focuses on complex chemical and pharmaceutical patent litigation matters. Notable results include a two-week jury trial win for Sunovion in Hatch-Waxman litigation against Mylan concerning the asthma drug Xopenex (levalbuterol), winning lost profits, plus a reasonable royalty and a jury finding of willful infringement. He has counselled clients regarding drug analogues, fusion proteins, recombinant DNA techniques and analytical methods and medical device technologies.
Tom also regularly presents on Hatch-Waxman issues at the ACI Paragraph IV litigation conferences in New York in 2014, 2011, 2008 and 2007, and at the Momentum Par. IV conference in NY in 2013.
WWL says: A veteran trial lawyers with a “first rate” practice
This biography is an extract from Who's Who Legal: Life Sciences which can be purchased from our Shop.